Counts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
Medicare to Cover Obesity Drugs for the First Time, Opening a Major New Market for Eli Lilly's Zepbound
Direct news · High influence · Long term
Employers Aren't Expanding GLP-1 Coverage: What It Means for Lilly and UnitedHealth
GLP-1 / obesity-drug demand · Medium influence · Long term
Medicare GLP-1 Coverage Bridge Expands Market for Eli Lilly's Mounjaro and Zepbound
Drug pricing / FDA / IRA · Medium influence · Long term
FDA Selects Eli Lilly and Regeneron for Manufacturing Facility Fast-Track Initiative
Direct news · Medium influence · Long term
CMS Proposes Extending Medicare Drug Price Negotiations to 2029, Pressuring Big Pharma Revenue
Drug pricing / FDA / IRA · Medium influence · Long term
Macro, commodity, FX and regulatory forces that moved LLY in this range, with the stories behind each.
Sign up free to track LLY, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track LLY for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
FDA Accepts Sandoz Generic Tirzepatide Application, Threatening Lilly's GLP-1 Franchise
Also monitored for LLY (no news in this range): FDA approvals & trial outcomes, 10-Year Treasury yield.
